Association of Preexisting Heart Failure With Outcomes in Older Patients With Diffuse Large B-Cell Lymphoma.
Sign Up to like & getrecommendations! Published in 2023 at "JAMA cardiology"
DOI: 10.1001/jamacardio.2023.0303
Abstract: Importance Anthracycline-containing regimens are highly effective for diffuse large B-cell lymphoma (DLBCL); however, patients with preexisting heart failure (HF) may be less likely to receive anthracyclines and may be at higher risk of lymphoma mortality.… read more here.
Keywords: lymphoma; diagnosis; large cell; mortality ... See more keywords
Global hypomethylation is an independent prognostic factor in diffuse large B cell lymphoma
Sign Up to like & getrecommendations! Published in 2017 at "American Journal of Hematology"
DOI: 10.1002/ajh.24751
Abstract: Global hypomethylation has been linked to disease progression in several cancers, but has not been reported for Diffuse Large B Cell Lymphoma (DLBCL). This study aimed to assess global methylation in DLBCL and describe its… read more here.
Keywords: methylation; global hypomethylation; cfdna; large cell ... See more keywords
A new prognostic model identifies patients aged 80 years and older with diffuse large B‐cell lymphoma who may benefit from curative treatment: A multicenter, retrospective analysis by the Spanish GELTAMO group
Sign Up to like & getrecommendations! Published in 2018 at "American Journal of Hematology"
DOI: 10.1002/ajh.25107
Abstract: The means of optimally managing very elderly patients with diffuse large B‐cell lymphoma (DLBCL) has not been established. We retrospectively analyzed 252 patients aged 80‐100 years, diagnosed with DLBCL or grade 3B follicular lymphoma, treated… read more here.
Keywords: lymphoma; treatment; prognostic model; large cell ... See more keywords
EBV‐positive diffuse large B‐cell lymphoma, not otherwise specified: 2022 update on diagnosis, risk‐stratification, and management
Sign Up to like & getrecommendations! Published in 2022 at "American Journal of Hematology"
DOI: 10.1002/ajh.26579
Abstract: Epstein Barr virus‐positive (EBV+) diffuse large B‐cell lymphoma (DLBCL), not otherwise specified (NOS) is an entity included in the WHO classification of lymphoid neoplasms since 2016. EBV+ DLBCL, NOS, is an aggressive B‐cell lymphoma associated… read more here.
Keywords: cell; cell lymphoma; large cell; diffuse large ... See more keywords
Sequence analyses of relapsed or refractory diffuse large B‐cell lymphomas unravel three genetic subgroups of patients and the GNA13 mutant as poor prognostic biomarker, results of LNH‐EP1 study
Sign Up to like & getrecommendations! Published in 2023 at "American Journal of Hematology"
DOI: 10.1002/ajh.26835
Abstract: Advances in molecular profiling of newly diagnosed diffuse large B‐cell lymphoma (DLBCL) have recently refine genetic subgroups. Genetic subgroups remain undetermined at the time of relapse or refractory (RR) disease. This study aims to decipher… read more here.
Keywords: refractory; three genetic; large cell; diffuse large ... See more keywords
Simplicity at the cost of predictive accuracy in diffuse large B‐cell lymphoma: a critical assessment of the R‐IPI, IPI, and NCCN‐IPI
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Medicine"
DOI: 10.1002/cam4.1271
Abstract: The international prognostic index (IPI) and similar models form the cornerstone of clinical assessment in newly diagnosed diffuse large B‐cell lymphoma (DLBCL). While being simple and convenient to use, their inadequate use of the available… read more here.
Keywords: ipi; ipi nccn; large cell; nccn ipi ... See more keywords
SGK1 mutation status can further stratify patients with germinal center B‐cell‐like diffuse large B‐cell lymphoma into different prognostic subgroups
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.4550
Abstract: There are over a 100 driver gene mutations in patients with diffuse large B‐cell lymphoma (DLBCL), but their clinical significance remains unclear. Here, we first analyzed the DLBCL dataset from the UK‐based Haematological Malignancy Research… read more here.
Keywords: cell; sgk1 mutation; large cell; diffuse large ... See more keywords
Patient‐reported outcomes provide prognostic information for survival in patients with diffuse large B‐cell lymphoma: Analysis of 1239 patients from the GOYA study
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.4692
Abstract: We investigated the prognostic value of pretreatment patient‐reported outcomes (PROs) in patients with diffuse large B‐cell lymphoma (DLBCL) receiving obinutuzumab/rituximab plus chemotherapy in the GOYA phase III study. read more here.
Keywords: reported outcomes; patient reported; cell lymphoma; large cell ... See more keywords
Identification of three small nucleolar RNAs (snoRNAs) as potential prognostic markers in diffuse large B‐cell lymphoma
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.5115
Abstract: Diffuse large B‐cell lymphoma (DLBCL) is a non‐Hodgkin lymphoma with high mortality rates. Small nucleolar RNAs (snoRNAs) are tumor‐specific biological markers, but there are few studies on the role of snoRNAs in DLBCL. read more here.
Keywords: lymphoma; small nucleolar; cell lymphoma; large cell ... See more keywords
Subcutaneous rituximab in patients with diffuse large B cell lymphoma and follicular lymphoma: Final results of the non‐interventional study MabSCale
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.5160
Abstract: Rituximab has become a standard treatment for non‐Hodgkin lymphoma. Clinical studies have demonstrated the efficacy of rituximab in combination with standard chemotherapies in the treatment of follicular lymphoma (FL) and diffuse large B cell lymphoma… read more here.
Keywords: lymphoma; cell lymphoma; follicular lymphoma; large cell ... See more keywords
Prognosis and complications of patients with primary gastrointestinal diffuse large B‐cell lymphoma: Development and validation of the systemic inflammation response index‐covered score
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Medicine"
DOI: 10.1002/cam4.5733
Abstract: This study aimed to evaluate the predictive value of systemic inflammation response index (SIRI) in primary gastrointestinal diffuse large B‐cell lymphoma (PGI‐DLBCL) patients and establish a highly discriminating risk prediction model. read more here.
Keywords: response index; primary gastrointestinal; inflammation response; diffuse large ... See more keywords